ECE2018 Poster Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (101 abstracts)
Efficacy and tolerability of cabergoline in a cohort of 160 prolactinomas at weekly doses of up to 9 mg
Lucio Vilar 1, , Clarice Vilar 2 , Luciano Albuquerque 1 , Ana Carolina Thé 1 , Erik Trovão 1 , Patricia Gadelha 1 , Icaro Sampaio 1 , Barbara Gomes 1 , Liana Ferreira 1 , Priscila Aroucha 1 , Raissa Lyra 2 , Maira Fonseca 1 & Ruy Lyra 1
1Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil; 2Pernambuco Endocrine Research Center, Recife, Brazil.
Background: Dopamine agonists are the mainstay of treatment for prolactinomas. Cabergoline (CAB) is preferable to bromocriptine due to its greater efficacy and better tolerability.
Subjects and methods: The aim of this retrospective open trial was to evaluate the efficacy and tolerability of CAB in a cohort of 160 patients with prolactinomas routinely followed in Pernambuco Endocrine Research Center and Division of Endocrinology, Hospital das Clinicas, Federal University, Recife, Brazil.
Results: A total of 160 patients (100 women and 60 men; mean age, 31.1±6.3 yrs; age range, 15–44; 86 micros and 74 macroprolactinomas) were enrolled. Overall, 7 patients (4.4%) were intolerant to CAB due to gastrointestinal and/or neurological side-effects (headaches and dizzness). Among the remaining patients, normalization of prolactin (PRL) levels was achieved by 115 patients (75.2%) at doses of up to 2 mg/week, whereas PRL normalization was found in 13 additional patients when CAB dose was increased to up to 3 mg/week. The remaining 25 patients were submitted to increasing doses of CAB up to 9 mg/week, 18 of whom (72%) reached PRL normalization. No patients benefited from weekly doses > 7 mg. Among responsive patients with macroprolactinomas, 82% experienced tumor shrinkage >50% whereas 55% had complete tumor disappearance. CAB doses > 3 mg/week were well tolerated and no significant valvular abnormalities were found despite the use of weekly doses as high as 9 mg.
Conclusions: In doses of up to 9 mg/week, longterm CAB therapy was well tolerated and enabled PRL normalization in 95% of patients with prolactinomas. No patients benefited from doses > 7 mg/week.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more